KNSA Q2 2019 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$39M

Net Income

-$37M

EPS (Diluted)

$-0.68

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$41M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$308M

Total Liabilities

$33M

Stockholders' Equity

$275M

Cash & Equivalents

$287M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$39M	-$22M	-82.5%
Net Income	-$37M	-$20M	-83.6%